Botanix Pharmaceuticals (BOT) Fundamentals 2026 — Revenue Analysis | SniperIQ
Botanix Pharmaceuticals (BOT) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$46M, trading at A$0.02 on the ASX. This SniperIQ fundamentals page covers Botanix Pharmaceuticals's valuation, profitability (net margin -404.7%), revenue (A$6M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Botanix Pharmaceuticals's market cap?
Botanix Pharmaceuticals (BOT) has a market capitalization of approximately A$46M, trading at A$0.02 on the ASX. Market cap moves with the live share price.
What is Botanix Pharmaceuticals's P/E ratio?
Botanix Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Botanix Pharmaceuticals?
Botanix Pharmaceuticals runs a net profit margin of -404.7%, a gross margin of -118.2%, and an operating margin of -380.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Botanix Pharmaceuticals generate?
Botanix Pharmaceuticals reported revenue of A$6M for fiscal year 2025, with net income of -A$86M and earnings per share (EPS) of -0.0468. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Botanix Pharmaceuticals pay a dividend?
Botanix Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Botanix Pharmaceuticals financially healthy?
Botanix Pharmaceuticals carries a debt-to-equity ratio of 0.57x and a current ratio of 2.56x, with a market beta of 0.86. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Botanix Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Botanix Pharmaceuticals (BOT) the key facts are: market cap A$46M, revenue A$6M, 52-week range 0.018-0.18. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Botanix Pharmaceuticals's full fundamentals live
Get Botanix Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.